Penetration of moxifloxacin into the human aqueous humour after oral administration

British Journal of Ophthalmology

Volumn 89, Issue 5, 2005, Pages 628-631

  Kampougeris, G ^a,b   Antoniadou, A ^c   Kavouklis, E ^b   Chryssouli, Z ^c   Giamarellou, H ^c  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGAR GEL DIFFUSION; AGED; ANTERIOR EYE CHAMBER; ANTIBIOTIC RESISTANCE; AQUEOUS HUMOR; ARTICLE; CATARACT EXTRACTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PENETRATION; EYE INFECTION; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; AQUEOUS HUMOR; AZA COMPOUNDS; CATARACT EXTRACTION; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; QUINOLINES;

EID: 17644398398     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2004.050054     Document Type: Article

References (26)

1. Marx JL. Endophthalmitis. In: Yanoff M, Duker JS, eds. Ophthalmology. London: Mosby, 1999:10.21.1-6.
2. Kanski JJ, Young JH, Vogel R. Penetration of intravenously administered cefoxitin into the aqueous humor of inflamed human eyes. Am J Ophthalmol 1982;94:516-18.
3. Aquilar HE, Meredith TA, Shaarawy A, et al. Vitreous cavity penetration of certazidime after intravenous administration. Retina 1995;15:154-9.
4. Alfaro DV, Hudson SJ, Rafanan MM, et al. The effect of trauma on the ocular penetration of intravenous ciprofloxacin. Am J Ophthalmol 1990;122:678-83.
5. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 1999;106:1313-18.
6. Gordon YJ. Vancomycin prophylaxis and emerging resistance: are ophthalmologists the villains? The heroes? Am J Ophthalmol 2001;131:371-6.
7. Lesk MR, Ammann H, Marcil G, et al. The penetration of oral ciprofloxacin into the aqueous humor, vitreous and subretinal fluid of humans. Am J Ophthalmol 1993;115:623-8.
8. Donnenfeld ED, Perry HD, Snyder RW, et al. Intracorneal, aqueous humor and vitreous humor penetration of topical and oral ofloxacin. Arch Ophthalmol 1997;115:173-6.
9. Fiscella RG, Nguyen TK, Cwik MJ, et al. Aqueous and vitreous penetration of levofloxacin after oral administration. Ophthalmology 1999;106:2286-90.
10. Klassen M, Edberg SC. Measurement of antibiotics in human body fluids: techniques and significance. In: Lorian V, eds. Antibiotics in laboratory medicine. Baltimore: William and Wilkins, 1996:230-95.
11. Al-Meshal MA, Ramadan MA, Lotfi KM, et al. Determination of meropenem in plasma by high-performance liquid chromatography and a microbiological method. J Clin Pharm Ther 1995;20:158-63.
12. Wong PY, Zhu M, Li RC. Pharmacokinetic and pharmacodynamic interactions between intravenous ciprofloxacin and oral ferrous sulfate. J Chemother 2000;12:286-93.
13. Mather R, Karenchak LM, Romanowski EG, et al. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002;133:463-66.
14. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001;32(Suppl 1):S39-46.
15. Hooper D. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001;32(Suppl 1):S9-15.
16. Garcia-Saenz MC, Arias-Puente A, Fresnadillo-Martinez M, et al. Human aqueous humor levels of oral ciprofloxacin, levofloxacin and moxifloxacin. J Cataract Refract Surg 2001;27:1969-74.
17. Hariprasad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch Ophthalmol 2003;121:345-50.
18. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new "respiratory quinolones". J Antimicrob Chemother 1999;43(Suppl B):1-11.
19. Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis 2001;32(Suppl 1):S51-63.
20. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996;122:1-17.
21. Andriole VT. Quinolones. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ, eds. Antibiotics and chemotherapy. Philadelphia: Churchill-Livingstone, 2003, Chapter 29.
22. Morlet N, Graham GG, Gatus B, et al. Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis. Antimicrob Agents Chemother 2000;44:1674-9.
23. Bron A, Talon D, Delbose B, et al. Intracameral penetration of ofloxacin in man. J Fr Ophtalmol 1987;10:443-6.
24. Endophthalmitis Vitrectomy Study Group. Results of the endophthalmitis vitrectomy study. A randomised trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-96.
25. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468-72.
26. Gavin JR, Kubin R, Choudri S, et al. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf 2004;27:671-86.